Benzenesulfonamide Compounds and the Use Thereof
First Claim
Patent Images
1. A compound having the Formula I:
- or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein;
R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, halogen, alkoxy, haloalkoxy, cyano, nitro, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxy;
R3 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylalkyl, 3-tetrahydrofuranylalkyl, alkylsulfonylaminoalkyl, aminocarbonylalkyl, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl;
Z is selected from the group consisting of Z1, Z2, Z3, and Z4 wherein;
Z1 is Z2 is Z3 is Z4 is R4 is selected from the group consisting ofhydrogen;
alkyl;
alkenyl;
hydroxyalkyl;
haloalkyl;
mercaptoalkyl;
aminoalkyl;
alkylaminoalkyl;
dialkylaminoalkyl;
alkoxyalkyl; and
phenyl optionally substituted with one or more substituents independently selected from the group consisting of alkyl, cycloalkyl, halogen, cyano, amino, alkylamino, dialkylamino, hydroxy, nitro, haloalkyl, and alkoxy; and
R5 is C3-7 cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl;
orR4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, and halogen;
orR4 and R5 together form a bridge —
CH2—
CHG1-CHG2-CH2—
, wherein G1 and G2 together with the carbon atoms to which they are attached form a fused phenyl group;
R6, R7, and R8 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, hydroxyalkyl, amino, aminoalkyl, alkylamino, and dialkylamino;
R9, R10, and R11 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, nitro, and hydroxy(C1-3)alkylamino;
Y is —
C(O)—
, —
COH—
or —
CH—
;
where when Y is —
C(O)—
, the bond between N and Y is a single bond and R12 is present; and
when Y is —
COH—
or —
CH—
, the bond between N and Y is a double bond and R12 is absent;
R12 is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl;
m is 0, 1, 2, or 3;
r is 0, 1, 2, or 3;
q is 0, 1, 2, or 3; and
p is 1 or 2 provided that 1) when Z is Z2, then none of R6, R7, or R8 is attached to the 1-position of the cycloalkyl ring;
2) when Z is Z3, Z3 is other than;
3) when Z is Z4, the compound is not N-cyclopropyl-N-{1-[(3-trifluoromethyl-4-methoxy)benzoyl]piperidin-4-yl}-3-trifluoromethylbenzenesulfonamide or N-cyclopropyl-N-[1-(4-dimethylaminobenzoyl)piperidin-4-yl]-3-trifluoromethylbenzenesulfonamide.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z, p and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
112 Citations
50 Claims
-
1. A compound having the Formula I:
-
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, halogen, alkoxy, haloalkoxy, cyano, nitro, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxy; R3 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylalkyl, 3-tetrahydrofuranylalkyl, alkylsulfonylaminoalkyl, aminocarbonylalkyl, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; Z is selected from the group consisting of Z1, Z2, Z3, and Z4 wherein; Z1 is Z2 is Z3 is Z4 is R4 is selected from the group consisting of hydrogen; alkyl; alkenyl; hydroxyalkyl; haloalkyl; mercaptoalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; alkoxyalkyl; and phenyl optionally substituted with one or more substituents independently selected from the group consisting of alkyl, cycloalkyl, halogen, cyano, amino, alkylamino, dialkylamino, hydroxy, nitro, haloalkyl, and alkoxy; and R5 is C3-7 cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl;
orR4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, and halogen;
orR4 and R5 together form a bridge —
CH2—
CHG1-CHG2-CH2—
, wherein G1 and G2 together with the carbon atoms to which they are attached form a fused phenyl group;R6, R7, and R8 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, hydroxyalkyl, amino, aminoalkyl, alkylamino, and dialkylamino; R9, R10, and R11 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, nitro, and hydroxy(C1-3)alkylamino; Y is —
C(O)—
, —
COH—
or —
CH—
;
wherewhen Y is —
C(O)—
, the bond between N and Y is a single bond and R12 is present; andwhen Y is —
COH—
or —
CH—
, the bond between N and Y is a double bond and R12 is absent;R12 is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl; m is 0, 1, 2, or 3; r is 0, 1, 2, or 3; q is 0, 1, 2, or 3; and p is 1 or 2 provided that 1) when Z is Z2, then none of R6, R7, or R8 is attached to the 1-position of the cycloalkyl ring; 2) when Z is Z3, Z3 is other than; 3) when Z is Z4, the compound is not N-cyclopropyl-N-{1-[(3-trifluoromethyl-4-methoxy)benzoyl]piperidin-4-yl}-3-trifluoromethylbenzenesulfonamide or N-cyclopropyl-N-[1-(4-dimethylaminobenzoyl)piperidin-4-yl]-3-trifluoromethylbenzenesulfonamide. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
-
-
7. The compound of any one of claims 1-6, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, cyano, alkoxy, haloalkoxy, nitro, amino, alkylamino, and dialkylamino.
-
8. The compound of claim 7, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, methyl, ethyl, fluoro, chloro, trifluoromethyl, difluoromethyl, fluoromethyl, cyano, nitro, methoxy and difluoromethoxy.
-
9. The compound of claim 8, wherein R1 is hydrogen and R2 is trifluoromethyl, or R1 and R2 are both hydrogen.
-
10. The compound of any one of claims 1-3, having the Formula III:
-
or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
-
-
11. The compound of any one of claims 1-3, 6, or 10, wherein Z=Z1 having the Formula IV:
-
or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
-
-
12. The compound of claim 11, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, cyano, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, and nitro;
- and R3 is selected from the group consisting of methyl, ethyl, iso-pentyl, iso-butyl, iso-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, cyclopropylethyl, methoxymethyl, methoxyethyl, hydroxymethyl, hydroxyethyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 2-tetrahydrofuranylethyl, methylsulfonamidomethyl, methylsulfonamidoethyl, aminocarbonylmethyl, and aminocarbonylethyl.
-
13. The compound of claim 11, wherein R4 is selected from the group consisting of
hydrogen; -
alkyl; alkenyl; hydroxyalkyl; haloalkyl; mercaptoalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; alkoxyalkyl; and phenyl optionally substituted with one or more substituents independently selected form the group consisting of alkyl, cycloalkyl, halogen, cyano, amino, alkylamino, hydroxy, nitro, haloalkyl, and alkoxy; and R5 is C3-7 cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl
-
-
14. The compound of claim 13, wherein R4 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, unsubstituted phenyl, and phenyl substituted with one or two substituents independently selected from the group consisting of alkyl, cycloalkyl, halogen, cyano, amino, alkylamino, dialkylamino, hydroxy, nitro, haloalkyl, and alkoxy.
-
15. The compound of claim 14, wherein R4 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl, hydroxymethyl, hydroxyethyl, and unsubstituted phenyl.
-
16. The compound of claim 13, wherein R5 is C3-7 cycloalkyl optionally substituted with one or two substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl.
-
17. The compound of claim 11, wherein R4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, and halogen.
-
18. The compound of claim 17, wherein R4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring substituted with one or two substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, and halogen.
-
19. The compound of claim 11, wherein R4 and R5 together form a bridge —
- CH2—
CHG1-CHG2-CH2—
, wherein G1 and G2 together with the carbon atoms to which they are attached form a fused phenyl group.
- CH2—
-
20. The compound of any one of claims 1-3, 6, or 10, wherein Z=Z2 having the Formula V:
-
or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
-
-
21. The compound of claim 20, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, cyano, alkoxy, haloalkoxy, nitro, amino, alkylamino, and dialkylamino;
- and R3 is selected from the group consisting of methyl, ethyl, iso-pentyl, iso-butyl, iso-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, cyclopropylethyl, methoxymethyl, methoxyethyl, hydroxymethyl, hydroxyethyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 2-tetrahydrofuranylethyl, methylsulfonamidomethyl, methylsulfonamidoethyl, aminocarbonylmethyl, and aminocarbonylethyl.
-
22. The compound of claim 20, wherein R6, R7, and R8 are each independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, hydroxy, hydroxy(C1-6)alkyl, amino, amino(C1-6)alkyl, C1-3 alkylamino, and di(C1-3)alkylamino.
-
23. The compound of claim 20, wherein r is 1.
-
24. The compound of claim 20, wherein r is 2.
-
25. The compound of any one of claims 1-3, 6 or 10, wherein Z=Z3 having the Formula VI:
-
or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
-
-
26. The compound of claim 25, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, cyano, alkoxy, haloalkoxy, nitro, amino, aminoalkyl, and dialkylamino;
- and R3 is selected from the group consisting of methyl, ethyl, iso-pentyl, iso-butyl, iso-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, cyclopropylethyl, methoxymethyl, methoxyethyl, hydroxymethyl, hydroxyethyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 2-tetrahydrofuranylethyl, methylsulfonamidomethyl, methylsulfonamidoethyl, aminocarbonylmethyl, and aminocarbonylethyl.
-
27. The compound of claim 25, wherein R9, R10, and R11 are each independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, halogen, halo(C1-6)alkyl, hydroxy, hydroxy(C1-6)alkyl, cyano, amino, amino(C1-6)alkyl, C1-3 alkylamino, nitro, di(C1-3)alkylamino, and hydroxy(C1-3)alkylamino.
-
28. The compound of claim 25, wherein Y is —
- C(O)—
.
- C(O)—
-
29. The compound of claim 25, wherein Y is —
- COH—
.
- COH—
-
30. The compound of claim 25, wherein Y is —
- CH—
.
- CH—
-
31. The compound of claim 25, wherein R12 is hydrogen or C1-6 alkyl.
-
32. The compounds of any one of claims 1-3, 6, or 10, wherein Z=Z4 having the Formula VII:
-
or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
-
-
33. The compound of claim 32, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, cyano, alkoxy, haloalkoxy, nitro, amino, alkylamino, and dialkylamino;
- and R3 is selected from the group consisting of methyl, ethyl, iso-pentyl, iso-butyl, iso-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, cyclopropylethyl, methoxymethyl, methoxyethyl, hydroxymethyl, hydroxyethyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 2-tetrahydrofuranylethyl, methylsulfonamidomethyl, methylsulfonamidoethyl, aminocarbonylmethyl, and aminocarbonylethyl.
-
34. The compound of claim 32, wherein R9, R10, and R11 are each independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, halogen, halo(C1-6)alkyl, hydroxy, hydroxy(C1-6)alkyl, cyano, amino, amino(C1-6)alkyl, C1-3 alkylamino, di(C1-3)alkylamino, nitro and hydroxy(C1-3)alkylamino.
-
35. The compound of any one of claims 1-3, wherein Z3 is
-
37. A pharmaceutical composition, comprising the compound of any of claims 1-36 and a pharmaceutically acceptable carrier.
-
38. A method of treating, preventing or ameliorating a disorder responsive to the blockade of calcium channels in a mammal suffering from said disorder, comprising administering to a mammal in need of such treatment, prevention or amelioration an effective amount of a compound of any of claims 1-36.
-
39. The method of claim 38, wherein a disorder responsive to the blockade of N-type calcium channels is treated, prevented or ameliorated.
-
40. A method for method for treating, preventing or ameliorating stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia in a mammal, comprising administering an effective amount of a compound of any of claims 1-36.
-
41. The method of claim 40, wherein the method is for treating, preventing or ameliorating pain selected from chronic pain, neuropathic pain, acute pain, and surgical pain.
-
42. A method of modulating calcium channels in a mammal, comprising administering to the mammal at least one compound of any one of claims 1-36.
-
43. The method of claim 42, wherein the N-type calcium channel is modulated.
-
44. A compound having the Formula I as claimed in claims 1-3, wherein the compound is 3H, 11C, or 14C radiolabeled.
-
45. A method of screening a candidate compound for the ability to bind to a receptor using a radiolabeled compound of claim 44, comprising a) introducing a fixed concentration of the radiolabeled compound to the receptor to form a mixture;
- b) titrating the mixture with a candidate compound; and
c) determining the binding of the candidate compound to said receptor.
- b) titrating the mixture with a candidate compound; and
-
46. A compound according to any one of the preceding claims 1 to 36 for the use as a medicament.
-
47. Use of a compound according to any one of the preceding claims 1 to 36 for the manufacture of a medicament for the treating, preventing or ameliorating of a disorder responsive to the blockade of calcium channels.
-
48. Use of a compound according to claim 47, wherein the disorder is a disorder responsive to the blockade of N-type calcium channels.
-
49. Use of a compound according to any one of claims 1 to 36 in the manufacture of a medicament for the treating, preventing or ameliorating stroke, neuronal damage resulting from head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension or cardiac arrhythmia in a mammal.
-
50. Use of a compound according to any one of claims 1 to 36 in the manufacture of a medicament for the treating, preventing or ameliorating pain selected from chronic pain, neuropathic pain, acute pain, and surgical pain.
-
2. A compound having the Formula I:
-
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, halogen, alkoxy, haloalkoxy, cyano, nitro, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxy; R3 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylalkyl, 3-tetrahydrofuranylalkyl, alkylsulfonylaminoalkyl, aminocarbonylalkyl, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; Z is selected from the group consisting of Z1, Z2, Z3, and Z4 wherein; Z1 is Z2 is Z3 is Z4 is R4 is selected from the group consisting of hydrogen; alkyl; alkenyl; hydroxyalkyl; haloalkyl; mercaptoalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; alkoxyalkyl; and phenyl optionally substituted with one or more substituents independently selected from the group consisting of alkyl, cycloalkyl, halogen, cyano, amino, alkylamino, dialkylamino, hydroxy, nitro, haloalkyl, and alkoxy; and R5 is C3-7 cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl;
orR4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl; R6, R7, and R8 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, hydroxyalkyl, amino, aminoalkyl, alkylamino, and dialkylamino; R9, R10, and R11 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxy(C1-3)alkylamino; Y is —
C(O)—
, —
COH—
or —
CH—
;
wherewhen Y is —
C(O)—
, the bond between N and Y is a single bond and R12 is present; andwhen Y is —
COH—
or —
CH—
, the bond between N and Y is a double bond and R12 is absent;R12 is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl; m is 0, 1, 2, or 3; r is 0, 1, 2, or 3; q is 0, 1, 2, or 3; and p is 1 or 2 provided that when Z is Z3, Z3 is other than;
-
-
3. A compound having the Formula I:
-
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, halogen, alkoxy, haloalkoxy, cyano, nitro, amino, aminoalkyl, alkylamino, dialkylamino, and hydroxy; R3 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylalkyl, 3-tetrahydrofuranylalkyl, alkylsulfonylaminoalkyl, aminocarbonylalkyl, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; Z is selected from the group consisting of Z1, Z2, and Z3, wherein; Z1 is Z2 is Z3 is R4 is selected from the group consisting of hydrogen; alkyl; alkenyl; hydroxyalkyl; haloalkyl; mercaptoalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; alkoxyalkyl; and phenyl optionally substituted with one or more substituents independently selected from the group consisting of alkyl, cycloalkyl, halogen, cyano, amino, alkylamino, dialkylamino, hydroxy, nitro, haloalkyl, and alkoxy; and R5 is C3-7 cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl;
orR4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring substituted with one or more substituents each independently selected from the group consisting of hydroxy, hydroxyalkyl, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl; R6, R7, and R8 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, hydroxyalkyl, amino, aminoalkyl, alkylamino, and dialkylamino; R9, R10, and R11 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; Y is —
C(O)—
or —
COH—
;
wherewhen Y is —
C(O)—
, the bond between N and Y is a single bond and R12 is present; andwhen Y is —
COH—
, the bond between N and Y is a double bond and R12 is absent;R12 is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl; m is 0, or 1, 2, or 3; r is 0, 1, 2, or 3; q is 0, 1, 2, or 3; and p is 1 or 2; provided that when Z is Z2, then none of R6, R7, or R8 is attached to the 1-position of the cycloalkyl ring.
-
-
36. A compound selected from the group consisting of:
-
N-cyclopropyl-N-{1-[3-(4-hydroxy-piperidin-1-yl)-propionyl]-piperidin-4-yl}-3-trifluoromethyl-benzenesulfonamide; N-cyclopropyl-N-{1-[3-(4-hydroxy-cyclohexylamino)-propionyl]-piperidin-4-yl}-3-trifluoromethyl-benzenesulfonamide; rac-N-[1-((1S,2R)-2-amino-cyclohexanecarbonyl)-piperidin-4-yl]-N-cyclopropyl-3-trifluoromethyl-benzenesulfonamide; rac-N-[1-((1S,2R)-2-amino-cyclopentanecarbonyl)-piperidin-4-yl]-N-cyclopropyl-3-trifluoromethyl-benzenesulfonamide; N-cyclopropyl-N-[1-(6-oxo-1,6-dihydro-pyridine-3-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzenesulfonamide; N-cyclopropyl-N-[1-(pyridine-2-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzenesulfonamide; N-cyclopropyl-N-[1-(pyridine-3-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzenesulfonamide; N-cyclopropyl-N-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzenesulfonamide; N-cyclopropyl-N-{1-[2-(2-hydroxy-ethylamino)-benzoyl]-piperidin-4-yl}-3-trifluoromethyl-benzenesulfonamide; rac-N-[1-((1S,2R)-2-amino-cyclopentanecarbonyl)-piperidin-4-yl}-N-isopropyl-3-trifluoromethylbenzenesulfonamide; N-cyclopropyl-N-[1-(2-nitro-benzoyl)-piperidin-4-yl]-3-trifluoromethylbenzenesulfonamide; N-[1-(2-amino-benzoyl)-piperidin-4-yl]-N-cyclopropyl-3-trifluoromethyl-benzenesulfonamide; N-[1-(2-cyclohexylamino-acetyl)-piperidin-4-yl]-N-isopropyl-3-trifluoromethylbenzenesulfonamide; N-{1-[2-(3-hydroxy-piperidin-1-yl)-acetyl]-piperidin-4-yl}-N-isopropyl-3-trifluoromethylbenzenesulfonamide; N-[1-(2-cyclopentylamino-acetyl)-piperidin-4-yl]-N-cyclopropyl-3-trifluoromethylbenzenesulfonamide; N-[1-(2-1,3-dihydro-isoindol-2-yl-acetyl)-piperidin-4-yl]-N-isopropyl-3-trifluoromethylbenzenesulfonamide; N-{1-[2-(3,3-difluoro-piperidin-1-yl)-acetyl]-piperidin-4-yl}-N-isopropyl-3-trifluoromethylbenzenesulfonamide; and N-{1-[2-(3,3-difluoro-pyrrolidin-1-yl)-acetyl]-piperidin-4-yl}-N-isopropyl-3-trifluoromethylbenzenesulfonamide; or a pharmaceutically acceptable salt, prodrug or solvate thereof.
-
Specification